The Valley Desk

NCT07252232 · Interventional trial

Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

Overall registry status Recruiting

Phase 3

Conditions PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer, Resectable Pancreatic Ductal Adenocarcinoma (PDAC), Resected Pancreatic Adenocarcinoma

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov